TrialJournal for immunotherapy of cancer2026

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study.

Zhigong Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.